Gerresheimer stock: Jefferies keeps Hold for Gerresheimer stock. It falls 1.71 percent.

Published on 10/20/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue hit EUR 578.00 million, down 5.86 percent. Gerresheimer stock was EUR 32.16 on October 20, 2026, down 1.71 percent versus Xetra close.

Jefferies Hold on September 30

Jefferies kept a Hold rating on September 30, 2026.
Second-quarter revenue reached EUR 578.00 million, down 5.86 percent year over year.
Gerresheimer stock costs EUR 32.16 at Lang & Schwarz on October 20, 2026 at 4:10 p.m. CEST, 1.71 percent below the Xetra close of October 19, 2026.
The Berenberg European Conference is scheduled for December 2, 2026.

Automatisierte Glasampullen-Produktionslinie in steriler Pharmafabrik — Gerresheimer AG mit ISIN DE000A0LD6E6 produziert Glasampullen in hochautomatisierter, steriler Pharmaverpackungsfertigung mit modernster Anlagentechnik, Illustration mit AI erstellt.

Jefferies kept a Hold rating on Gerresheimer on September 30, 2026, according to finanzen.net. Gerresheimer was trading at EUR 32.16 at Lang & Schwarz on October 20, 2026 at 4:10 p.m. CEST, down 1.71 percent versus the Xetra close of October 19, 2026 at EUR 32.72.

Revenue remains below last year

Gerresheimer reported second-quarter 2026 revenue of EUR 578.00 million, down 5.86 percent from EUR 614.00 million in the adjusted second quarter of 2025, according to Gerresheimer on September 30, 2026. Adjusted EBITDA reached EUR 102.00 million, compared with EUR 126.00 million a year earlier.

The sequential picture was firmer. Adjusted EBITDA rose from EUR 67.00 million in the first quarter of 2026 to EUR 102.00 million in the second quarter, while the adjusted EBITDA margin reached 17.60 percent.

Stock sits below its yearly high

The October 20, 2026 Lang & Schwarz price of EUR 32.16 was 1.89 percent below the 52-week high of EUR 32.78 and 116.72 percent above the 52-week low of EUR 14.83. Trading volume stood at 140,772 shares at the same timestamp.

Gerresheimer's market capitalization was EUR 1.1 billion on October 20, 2026. The company is listed on the Frankfurt Stock Exchange and operates in healthcare, with medical instruments and supplies as its industry classification.

Dates and peer valuation

Gerresheimer lists its half-year report for November 2026 and its third-quarter update for December 2026. The Berenberg European Conference is scheduled for December 2, 2026, according to Gerresheimer.

Comparison with peers

Gerresheimer: down 1.71 percent on October 20, 2026, market capitalization EUR 1.1 billion. SCHOTT Pharma: up 0.59 percent at EUR 25.65 on October 20, 2026, price-to-earnings ratio 28.30, market capitalization EUR 3.9 billion. Stevanato Group: down 0.26 percent at USD 18.97 on October 20, 2026, price-to-earnings ratio 35.20, market capitalization USD 5.2 billion.

What the numbers say

The share price is close to its 52-week high, but the second-quarter revenue decline shows that the recovery remains uneven across the business. Reuters reported on September 30, 2026 that stronger demand for drug delivery systems supported the quarter, while weaker demand for injection vials weighed on the business.

Trading position

For investors, the key contrast is between the EUR 102.00 million adjusted EBITDA result in the second quarter and revenue of EUR 578.00 million, which remained below the prior-year comparison. The next concrete calendar date is December 2, 2026.

The further course of trading is shown by the continuously updated real-time quote of Gerresheimer stock.